Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Réglementation et droit · 26/09/20161 min de lecture
Prospective Grant of Start-Up Exclusive Evaluation Patent License: Development of Autologous Tumor-reactive T Cells Isolated From Peripheral Blood for the Treatment of Metastatic Follicular Thyroid Cancer and Metastatic Soft Tissue Sarcomas
Traduction automatique locale · Langue originale de la source
Résumé
The National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-up Exclusive Evaluation Patent License to MedGene Therapeutics, Inc. ("MedGene") located in Bethesda, MD to practice the inventions embodied in the patent applications listed Supplementary Information section of this notice.
Langue originale de la source: Federal Register — All DocumentsOuvrir le communiqué original →